Read this leaflet carefully, and take this medicine under the doctor or pharmacists’ direction
Generic Name: Tongxinluo Capsules
Chinese Pinyin: Tongxinluo Jiaonang
[Ingredients] Ginseng, Leech, Scorpion, Red Peony Root, Cicada Slough, Ground Beetle, Centipede, Sandalwood, Rosewood, Frankincense Olibanum(processed), Spine Date Seed (stir-baked), Borneol
[Description] Capsules with brown powdered content; odour, aromatic, slightly stinking; taste, slightly salty and bitter.
[Functions and Indications ] To replenish qi and promote blood circulation, and dredge meridians to kill pain. It is used for angina pectoris in coronary heart disease caused by a deficiency of heart-qi and blockage of meridians by stagnated blood with manifestations of constriction, fixed stabbing or colic pain in the chest, palpitation, spontaneous sweating, shortness of breath, lassitude, dark purple tongue or ecchymosis, thready and unsmooth pulse or knotted and intermittent pulse; stroke due to a deficiency of qi and stagnated blood blocking meridians with manifestations of hemiplegia or numbness of one side of the body, deviated mouth and tongue and dysphasia.
[Administration and Dosage] For oral administration, 2-4 capsules once, 3 times daily.
[Adverse Reactions] Stomach discomfort may emerge in individual patient.
[Contraindication] Contraindicated for patients with hemorrhage, pregnant women, women during periods, and stroke patients from yin deficiency and fire hyperactivity.
[Precautions] Take the medicine after meals if the stomach is discomfortable after taking it.
[Pharmacological Actions] Non-clinical pharmacodynamics test showed that: It can decrease the degree of myocardial ischemia (MI) of canine and dog model of acute myocardial infarction, diminish the extent of myocardial ischemia (MI) and improve oxygen-supply and blood-supply, increase coronary blood flow(CBF) and the function of left ventricle; It can diminish the area of no-reflow after acute myocardial infarction and reperfusion in the experiment with mini-swine model and decrease the size of myocardial infarction(MI); It can restrain proliferation of myocardial collagenous fibers after myocardial infarction in rats, diminish deposition of collagen protein, decrease the content of AngiotensinⅡon cardiac muscle (CM), restrain reconstruction of cardiac ventricle and improve the function of heart; For local cerebral ischemic rat model, it can diminish the extent of infarction, decrease permeability of cerebral vessels and brain edema; For global cerebral ischemic in mice, it can mitigate pathological lesions such as denaturalization and necrosis of nerve cell and less of nissl body, improve neuroethology, protect ischemic brain tissue, increase the activity of Superoxide dismutase (SOD) of brain tissue, and reduce the content of malondialdehyde (MDA); For rat with hyperlipemiat, it can decrease total cholesterol and low density lipoprotein (LDL), increase high density lipoprotein(HDL), restrain thrombosis and platelet aggregation in rat’s body.
In addition, it is shown by the exploratory study of mechanism of action for the medicine that: for rat model with cerebral middle artery thrombus, it can reduce the content of excitatory amino acid and endothelin(ET), restrain the expression of endothelin gene, for the cerebral ischemic model of rat with middle cerebral artery thrombus, it can promote the expression of vascular endothelial growth factor (VEGF), protect the capillary endothelial cell in brain and promote neogenesis of blood capillary; Improve the endothelium function of atherosclerosis in rabbit model, and decrease the damage to the function of endothelium dependent vasodilatation of hypercholesterolemia. Through improving the expression of endothelial nitricoxide synthase (eNOS) gene in myocardial ischemic mice, it can increase the activity of endothelial nitricoxide synthase (eNOS) and the level of nitric oxide (NO) in blood plasma and tissue; It can decrease the level of total cholesterol (TC) in blood, LDL cholesterol (LDL-C) as well as endothelin (ET) and increase the level of NO through restraining the expression of mitogen-activated protein kinase (MAPK) and vascular intima proliferation after angioplasty in rabbit; For vulnerable plaques rabbit model, the medicine can play roles in stabilizing the vulnerable plaque though decreasing intracellular lipid content in plaque as well as blood-fat and plasma fibrinogen level, increasing the thickness of plaque fiberous coat and restraining the expression of inflammatory factor; It can restrain coronary artery spasm (CAS) of mini-swine induced by thrombotonin (5-HT); Through the above mentioned various functions, the medicine can exert its effect on protecting heart and brain as well as restraining the formation of thrombus.
[Storage] Preserve in tightly closed containers.
[Package] Aluminium-plastic package, 30 capsules/box.
[Shelf life] 36 months
[Executive Standard] Chinese Pharmacopoeia 2010, VolumeⅠ
[Approval No.] GYZZ Z19980015
Company name: Shijiazhuang Yiling Pharmaceutical Co., Ltd.
Manufacture address: No.238 Tianshan street, New and high development area, Shijiazhuang, Hebei, China.
Tel: 800 8038581 +86 311 85901719 400 8165108
Fax:+86 311 85901719
Registration address: No.238 Tianshan street, New and high development area, Shijiazhuang, Hebei, China.
Shijiazhuang Yiling Pharmaceutical Co., Ltd.